CanDriS: posterior profiling of cancer-driving sites based on two-component evolutionary model

Author:

Zhao Wenyi1,Yang Jingwen2,Wu Jingcheng3,Cai Guoxing3,Zhang Yao3,Haltom Jeffrey4,Su Weijia4,Dong Michael J4,Chen Shuqing3,Wu Jian5,Zhou Zhan6,Gu Xun4

Affiliation:

1. College of Pharmaceutical Sciences & College of Computer Science and Technology, Zhejiang University, China

2. MOE Key Laboratory of Contemporary Anthropology, Human Phenome Institute, School of Life Sciences, Fudan University, China

3. College of Pharmaceutical Sciences, Zhejiang University, China

4. Department of Genetics, Development and Cell Biology, Iowa State University, Ames, 12 Iowa 50011, USA

5. College of Computer Science and Technology & School of Medicine, Zhejiang University, China

6. College of Pharmaceutical Sciences, Innovation Institute for Artificial Intelligence in Medicine, Alibaba-Zhejiang University Joint Research Center of Future Digital Healthcare, Zhejiang University, China

Abstract

Abstract Current cancer genomics databases have accumulated millions of somatic mutations that remain to be further explored. Due to the over-excess mutations unrelated to cancer, the great challenge is to identify somatic mutations that are cancer-driven. Under the notion that carcinogenesis is a form of somatic-cell evolution, we developed a two-component mixture model: while the ground component corresponds to passenger mutations, the rapidly evolving component corresponds to driver mutations. Then, we implemented an empirical Bayesian procedure to calculate the posterior probability of a site being cancer-driven. Based on these, we developed a software CanDriS (Cancer Driver Sites) to profile the potential cancer-driving sites for thousands of tumor samples from the Cancer Genome Atlas and International Cancer Genome Consortium across tumor types and pan-cancer level. As a result, we identified that approximately 1% of the sites have posterior probabilities larger than 0.90 and listed potential cancer-wide and cancer-specific driver mutations. By comprehensively profiling all potential cancer-driving sites, CanDriS greatly enhances our ability to refine our knowledge of the genetic basis of cancer and might guide clinical medication in the upcoming era of precision medicine. The results were displayed in a database CandrisDB (http://biopharm.zju.edu.cn/candrisdb/).

Funder

Key Research and Development Program of Zhejiang Province

National Natural Science Foundation of China

Zhejiang Provincial Natural Science Foundation of China

Fundamental Research Funds for the Central Universities

Alibaba-Zhejiang University Joint Research Center of Future Digital Healthcare

Publisher

Oxford University Press (OUP)

Subject

Molecular Biology,Information Systems

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3